Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Mimedx (MDXG) Equity Average (2016 - 2025)

Historic Equity Average for Mimedx (MDXG) over the last 14 years, with Q3 2025 value amounting to $227.8 million.

  • Mimedx's Equity Average rose 3051.79% to $227.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $227.8 million, marking a year-over-year increase of 3051.79%. This contributed to the annual value of $167.9 million for FY2024, which is 16924.29% up from last year.
  • According to the latest figures from Q3 2025, Mimedx's Equity Average is $227.8 million, which was up 3051.79% from $209.7 million recorded in Q2 2025.
  • In the past 5 years, Mimedx's Equity Average ranged from a high of $227.8 million in Q3 2025 and a low of -$18.8 million during Q4 2022
  • Over the past 5 years, Mimedx's median Equity Average value was -$3.7 million (recorded in 2022), while the average stood at $66.9 million.
  • Its Equity Average has fluctuated over the past 5 years, first plummeted by 55504.72% in 2022, then surged by 317911.08% in 2024.
  • Mimedx's Equity Average (Quarter) stood at -$2.9 million in 2021, then tumbled by 555.05% to -$18.8 million in 2022, then skyrocketed by 484.04% to $72.0 million in 2023, then surged by 159.72% to $187.1 million in 2024, then increased by 21.77% to $227.8 million in 2025.
  • Its last three reported values are $227.8 million in Q3 2025, $209.7 million for Q2 2025, and $197.9 million during Q1 2025.